TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03090100
Drug: Secukinumab
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive 2 injections of active secukinumab at Weeks 0, 1, 2, 3, 4 and every 4 weeks (q4w) thereafter through Week 44.
Study: NCT02965443
Drug: Dapagliflozin 10 mg + Saxagliptin 5 mg
Normalized name: dapagliflozin / sAXagliptin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 24 weeks intervention with Dapagliflozin 10 mg + Saxagliptin 5 mg
Study: NCT01458899
Drug: TC-5214
Normalized name: TC-6987
DrugBank: TC-6987 (DB14854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets, single 4mg dose
Study: NCT02506816
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug exposure has a limited duration 28 (+/- 5) days and at lower dose (600mg/day) than therapeutical accepted (800mg/day).
Study: NCT02212587
Drug: TOBI
Normalized name: Tobi
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: New inhalation devices such as the podhaler can administer tobramycin inhalation powder TIP/TOBI and achieve very high sputum drug levels. TOBI will be administered using the Podhaler
Study: NCT02750891
Drug: DSP-7888
Normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase1 portion: 1.75 or 3.5 mg/body, Id every 1-4 weeks Phase 2 portion: recommended phase 2 dose, Id every 1-4 weeks
Study: NCT01652664
Drug: Travoprost 0.004% PQ ophthalmic solution
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01652664
Drug: Timolol, 0.5% or 0.25% ophthalmic solution
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients 2 months to \< 3 years of age received 0.25%
Study: NCT01652664
Drug: Travoprost Vehicle
Normalized name: Travoprost
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Inactive ingredients used to maintain masking
Study: NCT02357069
Drug: Enbrel
Normalized name: Enbrel
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept
Study: NCT00297037
Drug: Pimecrolimus 1% cream
Normalized name: PIMECROLIMUS 1% CREAM,TOP
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pimecrolimus cream or matching placebo BID for 6 weeks
Study: NCT00668941
Drug: Teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teriparatide will be given subcutaneously in 20-mcg doses either continuously or cyclically.
Study: NCT00668941
Drug: Alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will take 70 mg per week of alendronate for 48 months.
Study: NCT00206453
Drug: Taxotere
Normalized name: Taxotere
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy IV
Study: NCT00528723
Drug: salbutamol 100 mcg
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To be used as needed for symptom relief
Study: NCT03307629
Drug: NOX66
Normalized name: Noxafil
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: NOX66 delivered as rectal suppository.
Study: NCT00069992
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine 30mg/m2 Day -5 to -2
Study: NCT02212678
Drug: N-acetylcysteine capsule
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine capsule
Study: NCT03166111
Drug: lidocaine gel
Normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: syringe filled with 5 ml gel to be self-administered vaginal 10 minutes prior to insertion
Study: NCT03591172
Drug: Propolis
Normalized name: propolis
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Using propolis as a final irrigation in revascularization
Study: NCT03591172
Drug: Nano-propolis
Normalized name: propolis
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Using Nano-propolis as a final irrigation in revasculariztion
Study: NCT03591172
Drug: saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Using saline as a final irrigation in revasculariztion
Study: NCT02753127
Drug: Napabucasin
Normalized name: Napabucasin
DrugBank: Napabucasin (DB12155)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 12 hours (480 mg total daily dose).
Study: NCT02753127
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02753127
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01670565
Drug: Belimumab
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Belimumab (Benlysta®) decreases B-Cell survival and has been FDA approved for the treatment of systemic lupus erythematosus, another rheumatic autoimmune disease. Belimumab is a recombinant, fully human monoclonal antibody; it binds to the soluble human B lymphocyte stimulator (BLyS) with high affinity and inhibits its biologic activity. Prior research provides a robust rationale for the investigation of belimumab in combination with MMF (Cellcept ®) for the treatment of early diffuse cutaneous systemic sclerosis.
Study: NCT01670565
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients received background MMF therapy, some who were naive to MMF were titrated up to 1,000 mg twice daily and others had been receiving MMF at \<2,000 mg/day for \<3 months. MMF was chosen so that background therapy would be uniform and not a further source of variability in the small study.
Study: NCT03694873
Drug: Tramadol Hydrochloride
Normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: one tablet of Tramadol 100 mg (Tramaw, Global Napi, Giza,Egypt) administered orally immediately, 12 h and 24 h after randomization.
Study: NCT02229942
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction with two infusions two weeks apart, rituximab 500 mg/m2 (max 1000 mg).~Maintenance with rituximab infusions (500 mg fixed dose) at 3, 6, 9 and 12 months.
Study: NCT02694146
Drug: Platelet rich plasma
Normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet rich plasma (PRP) is a platelet concentrated obtained from autologous blood centrifugation. This concentration technique provides larger amounts of biologically active molecules, mainly growth factors that are responsible for tissue repair. PRP (platelet rich plasma) contains a higher concentration of platelets from baseline (150,000-350,000 / ul).
Study: NCT01837628
Drug: Lidocaine Gel
Normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01837628
Drug: Paraffin Oil
Normalized name: Paraffin Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01549964
Drug: Fasiglifam (TAK-875)
Normalized name: Fasiglifam
DrugBank: Fasiglifam (DB12491)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasiglifam (TAK-875) tablets
Study: NCT01549964
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sitagliptin tablets
Study: NCT02972632
Drug: Vortioxetine
Normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vortioxetine tablet
Study: NCT01041872
Drug: Propofol Astrazeneca plain
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
Study: NCT01041872
Drug: Propofol Astrazeneca plus lidocaine
Normalized name: Propofol
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
Study: NCT01041872
Drug: Propofol-lipuro B. Braun plain
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
Study: NCT01041872
Drug: Propofol-lipuro B. Braun plus lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
Study: NCT01041872
Drug: Propofol Fresenius plain
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
Study: NCT01041872
Drug: Propofol Fresenius plus lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
Study: NCT03211949
Drug: Scandicaine
DrugBank: Mepivacaine (DB00961)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 ml of scandicaine 1.5 % is deposited in an inplane technique around the medial antebrachial cutaneous nerve with a 22 G sonoplex needle as a surplus to an axillary block
Study: NCT00370253
Drug: Terlipressin
Normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mg/4 h per day
Study: NCT00370253
Drug: Noradrenalin
Normalized name: Noradrenaline
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0,1 mcg/kg/min
Study: NCT00232310
Drug: CELIVARONE (SSR149744C)
Normalized name: Celivarone
DrugBank: Celivarone (DB16012)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00001893
Drug: TNFR:Fc
Normalized name: rhu TNFR:Fc
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00579111
Drug: Campath
Normalized name: Campath
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg/day IV daily for 3 days on days -6 to D-4. Campath may be omitted from the conditioning regimen for patients with malignant diseases and matched related donor transplants
Study: NCT00579111
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3.2 mg/kg/day IV daily for 2 days, infused over 3 hours, on Day -5 and Day -4
Study: NCT00579111
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mg/m2/day IV daily for 4 days on Day -5 to D -2
Study: NCT00579111
Drug: FK-506
Normalized name: FK-960
DrugBank: FK-960 (DB06465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK-506 at a dose of 0.03 mg/kd/day will be administered via continuous infusion over 24 hours from 4pm on Day -2 until engraftment or when the patient is able to take PO, then 0.03 mg/kg PO every 12 hours.
Study: NCT04327999
Drug: Artificial Tears
Normalized name: Artificial Tears
DrugBank: Propylene glycol (DB01839)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-Administered - utilizing eye drop preservative free vials
Study: NCT00129363
Drug: Carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00532285
Drug: Paclitaxel/Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment will be delivered in the outpatient setting. Each three-week cycle consists of paclitaxel 80 mg/m2 (day 1, 8) and gemcitabine 1200 mg/m2 (day1, 8).Patients will receive four cycles of therapy unless there is any evidence of no response (SD or PD) or unacceptable toxicity defined as unpredictable, irreversible, or Grade 4, or noncompliance by patient with protocol requirements.
Study: NCT01430013
Drug: Endostar and CHOPT
Normalized name: cytarabine and daunorubicin
DrugBank: Endostar (DB11727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endostar 7.5mg/m2, for iv for continuous 14 days cyclophosphamide, pirarubicin, vincristine, teniposide, prednisone
Study: NCT01498952
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib is a tyrosine kinase inhibitor, anti-angiogenic, VEGF inhibitor
Study: NCT00579826
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole 2.5 mg tablet daily. Then optional open label letrozole for another 6 months.
Study: NCT02105974
Drug: Fluticasone Furoate/Vilanterol
Normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mcg FF micronized drug blended with lactose per blister in one strip and 25 mcg VI micronized drug blended with lactose and magnesium stearate per blister in another strip, administered together by ELLIPTA™ inhaler
Study: NCT02060032
Drug: 1.2% Atorvastatin local drug delivery
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00440310
Drug: Talaporfin sodium
Normalized name: Talaporfin
DrugBank: Talaporfin (DB11812)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: LS11 (Talaporfin Sodium) dose is 1mg/kg administered intravenously slow push (3-5 minutes).
Study: NCT00044187
Drug: Sibutramine
Normalized name: Sibutramine
DrugBank: Sibutramine (DB01105)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01650415
Drug: Erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice a week for 1 month
Study: NCT01650415
Drug: Placebo erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice a week for 1 month
Study: NCT01513681
Drug: Lamotrigine
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine Tablets 200 mg
Study: NCT00697437
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 70mg q3wx 1 dose
Study: NCT00697437
Drug: Ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 doses of oral ketoconazole 200mg bid starting 2 days before, and with 1 dose to be completed after, docetaxel infusion
Study: NCT04566653
Drug: Lokelma® 5 g/45mL water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: K+ binder, not for treatment but for tasting (sip-and-spit taste test)
Study: NCT04566653
Drug: Lokelma® 10 g/45 mL water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: K+ binder, not for treatment but for tasting (sip-and-spit taste test)
Study: NCT04566653
Drug: Veltassa® 8,4 g/80mL water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: K+ binder, not for treatment but for tasting (sip-and-spit taste test)
Study: NCT04566653
Drug: Sodium Polystyrene Sulphonate 15g/60 mL water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: K+ binder, not for treatment but for tasting (sip-and-spit taste test)
Study: NCT00149019
Drug: Cell therapy with bispecific antibodies
Normalized name: Activated natural killer cell therapy
DrugBank: Activated natural killer cell therapy (DB17172)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01352637
Drug: DCS (D-Cycloserine ) + Prolonged Imaginal Exposure
Normalized name: DCS
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg DCS (taken once a week on the day of the therapy session) + Prolonged Imaginal Exposure
Study: NCT01352637
Drug: DCS (D-Cycloserine ) + Virtual Reality Exposure
Normalized name: DCS
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg DCS (taken once a week on the day of the therapy session) + Virtual Reality Exposure
Study: NCT00289809
Drug: combination of TLC D-99 and Ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * TLC D-99: 40 mg/m2 Day 1 every 3 weeks;~* Ifosfamide: 3000 mg/m2 Day 1, 2, 3 every 3 weeks
Study: NCT02537405
Drug: Rivaroxaban (BAY 59-7939)
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban granule 10mg for one day
Study: NCT02537405
Drug: Rivaroxaban (Xarelto, BAY 59-7939)
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban tablet 10mg for one day
Study: NCT00136968
Drug: Voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00624676
Drug: 5% benzoyl peroxide gel
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once a day
Study: NCT02120976
Drug: JTT-252 or Placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will receive JTT-252 or Placebo
Study: NCT02120976
Drug: JTT-252
Normalized name: JTT-251
DrugBank: JTT-251 (DB18174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive JTT-252
Study: NCT00003814
Drug: eflornithine
Normalized name: Eflornithine
DrugBank: Eflornithine (DB06243)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00363454
Drug: Triciribine Phosphate Monohydrate
Normalized name: Triciribine phosphate
DrugBank: Triciribine (DB12405)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 Cycles @ 28 days. Level 1: 15 mg/m\^2; Level 2: 25 mg/m\^2; 35 mg/m\^2; 45 mg/m\^2.
Study: NCT03902080
Drug: Vibegron
Normalized name: Vibegron
DrugBank: Vibegron (DB14895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral administration
Study: NCT00332709
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 mg/day for 3 years
Study: NCT02105974
Drug: Vilanterol
Normalized name: Vilanterol
DrugBank: Vilanterol (DB09082)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mcg of Vilanterol micronized drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister in one strip and lactose in another strip, administered together by ELLIPTA™ inhaler
Study: NCT01990157
Drug: TAB08
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly intravenous administration in escalating doses.
Study: NCT03364868
Drug: Oral Insulin
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: treatment starting at 4 months - 7 months until age 3.0 years; dose escalation scheme: daily treatment with 7.5 mg or placebo for 2 months; increasing to daily treatment with 22.5 mg or placebo for the following 2 months; increasing to daily treatment with 67.5 mg or placebo until the end of the treatment period.
Study: NCT00254410
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine 25 mg/m2 on Days 2,3,4 i.v. 5-30 mins for course 1, and on Days 1 - 3 for courses 2 - 6
Study: NCT00254410
Drug: Mitoxantrone
Normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitoxantrone 6 mg/m2 on Day 2 i.v. 30-60 mins for course 1, and on Day 1 for courses 2 - 6.
Study: NCT01203592
Drug: Albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg twice daily by mouth for adults. The dose for children 6 to 12 years is 2 mg two or three times daily; the dose for children 2 to 6 years is 0.1 mg/kg/day (maximum 2 mg) three times daily.
Study: NCT00254410
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375 mg/m2 on Day 1 i.v. 2-6 hours for course 1 and 500 mg/m2 on Day 1 for courses 2 - 6.
Study: NCT00254410
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pegylated Filgrastim - 6 mg on Day 4,s.c. for course 1 and on Day 3 for courses 2 - 6.
Study: NCT01001702
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Flexible dose between 5 mg and 30 mg Aripiprazole tablets.
Study: NCT01458873
Drug: sodium bicarbonate 4.2%
Normalized name: Sodium Bicarbonate 4.2% Intravenous Solution
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: diluted sodium bicarbonate 50 ml
Study: NCT00635973
Drug: Gefitinib (Iressa)
Normalized name: gefitinib Oral Tablet [Iressa]
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iressa
Study: NCT02243228
Drug: GM-CSF
Normalized name: GM-CSF
DrugBank: Regramostim (DB05386)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02661594
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Positive control for assay sensitivity
Study: NCT01458873
Drug: diluted sodium bicarbonate 2.1%
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50ml
Study: NCT01726738
Drug: BRAF inhibitor dabrafenib and MEK inhibitor trametinib
Normalized name: Mitogen-activated protein kinase (MEK) inhibitors
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive the BRAF inhibitor dabrafenib and MEK inhibitor trametinib orally at the RP2D determined in the Phase I/II study (BRF113220): trametinib 2mg QD and dabrafenib 150 mg BID on a continuous basis. A cycle will be defined as 3 weeks in duration. Cycles will be repeated until disease progression (clinical or radiological). Patients may remain on treatment after progression (at the discretion of the investigator) as long as they are still experiencing clinical benefit.
Study: NCT00831532
Drug: Dimebon
Normalized name: Dimebon
DrugBank: Latrepirdine (DB11725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimebon 5mg in healthy controls
Study: NCT00831532
Drug: Dimebon
Normalized name: Dimebon
DrugBank: Latrepirdine (DB11725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimebon 5mg in mild hepatic impairment patients